ImmunoGen Inc.
About ImmunoGen Inc.
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is being advanced to Phase 3 testing for FRα-positive platinum-resistant ovarian cancer, and is also in Phase 1b/2 testing in combination regimens for earlier-stage disease. The Company's ADC technology is used in three other clinical-stage ImmunoGen product candidates, in Roche's marketed product, Kadcyla®, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda.
608 articles about ImmunoGen Inc.
-
ImmunoGen, Inc. Announces Webcast Of Presentation At The Lazard Capital Markets Third Annual Life Sciences Conference
11/21/2006
-
ImmunoGen, Inc. Announces Presentation Of HuN901-DM1 Clinical Data At EORTC-NCI-AACR Conference Showing Compound Is Well Tolerated And Demonstrates Anticancer Activity
11/10/2006
-
ImmunoGen, Inc. Announces Presentation Of HuC242-DM4 Clinical Data At EORTC-NCI-AACR Conference
11/8/2006
-
ImmunoGen, Inc. Reports First Quarter Fiscal Year 2007 Financial Results
11/3/2006
-
ImmunoGen, Inc. Announces Webcast Of Presentation At The Cowen & Co. 7th Annual Global Health Care Conference
11/1/2006
-
ImmunoGen, Inc. Announces Conference Call To Discuss Its First Quarter Fiscal Year 2007 Financial Results
10/26/2006
-
Sanofi-Aventis (France) Licenses Broader Access To ImmunoGen, Inc.'s Antibody Humanization Technology
10/18/2006
-
ImmunoGen, Inc. Announces Webcast Of Its Presentation At The Biotechnology Industry Organization (BIO) Investor Forum 2006
10/12/2006
-
ImmunoGen, Inc. Announces Initiation Of Clinical Testing Of AVE1642 Anticancer Compound In Collaboration With Sanofi-Aventis (France)
10/5/2006
-
ImmunoGen, Inc. Announces Sanofi-Aventis (France) Extendeds The Term Of Its Research Collaboration With The Company; Immunogen Gets $10 Million More
8/31/2006
-
ImmunoGen, Inc. Reports Fourth Quarter And Fiscal Year 2006 Financial Results; Company Provides Business Update
8/11/2006
-
ImmunoGen, Inc. Announces Conference Call To Discuss its Fourth Quarter And Fiscal Year 2006 Financial Results
8/3/2006
-
ImmunoGen, Inc. Grants Biotest AG Rights To Use ImmunoGen TAP Technology To Develop Novel Anticancer Therapeutics; ImmunoGen To Receive Up To $35.5 Million
7/11/2006
-
ImmunoGen, Inc. To Present At Needham & Company, LLC's Fifth Annual Biotechnology And Medical Technology Conference
6/8/2006
-
The Day In Review: Northstar Neuroscience, Inc. IPO Very Successful
5/5/2006
-
ImmunoGen, Inc. To Develop Commercial-Scale Manufacturing Process For Trastuzumab-DM1 For Genentech, Inc.; Agreement Worth $44 Million
5/5/2006
-
ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2006 Financial Results
5/5/2006
-
ImmunoGen, Inc. Announces Conference Call To Discuss Its Third Quarter Fiscal Year 2006 Financial Results
4/27/2006
-
ImmunoGen, Inc. Announces Eight Posters To Be Presented At AACR On Its TAP Technology And On Compounds In Development
4/3/2006
-
ImmunoGen, Inc. Announces Extension Of Technology Access Agreement By Millennium Pharmaceuticals, Inc. (Cambridge, Massachusetts)
3/29/2006